Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Galsky, Matthew D., Daneshmand, Siamak, Izadmehr, Sudeh, Gonzalez-Kozlova, Edgar, Chan, Kevin G., Lewis, Sara, Achkar, Bassam El, Dorff, Tanya B., Cetnar, Jeremy Paul, Neil, Brock O., D’Souza, Anishka, Mamtani, Ronac, Kyriakopoulos, Christos, Jun, Tomi, Gogerly-Moragoda, Mahalya, Brody, Rachel, Xie, Hui, Nie, Kai, Kelly, Geoffrey, Horwitz, Amir, Kinoshita, Yayoi, Ellis, Ethan, Nose, Yohei, Ioannou, Giorgio, Cabal, Rafael, Haines, G. Kenneth, Wang, Li, Mouw, Kent W., Samstein, Robert M., Mehrazin, Reza, Bhardwaj, Nina, Yu, Menggang, Zhao, Qianqian, Kim-Schulze, Seunghee, Sebra, Robert, Zhu, Jun, Gnjatic, Sacha, Sfakianos, John, Pal, Sumanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667093/
https://www.ncbi.nlm.nih.gov/pubmed/37783966
http://dx.doi.org/10.1038/s41591-023-02568-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667093/
https://www.ncbi.nlm.nih.gov/pubmed/37783966
http://dx.doi.org/10.1038/s41591-023-02568-1

Ejemplares similares